Literature DB >> 31666343

The child with immune thrombocytopenia: to treat or not to treat, is that still the question?

Nichola Cooper1, Douglas B Cines2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31666343      PMCID： PMC6821618          DOI： 10.3324/haematol.2019.229179

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  23 in total

Review 1.  Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.

Authors:  Cindy E Neunert; Melissa J Rose
Journal:  Blood Adv       Date:  2019-06-25

Review 2.  A review of the management of childhood immune thrombocytopenia: how can we provide an evidence-based approach?

Authors:  Nichola Cooper
Journal:  Br J Haematol       Date:  2014-04-25       Impact factor: 6.998

Review 3.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

Authors:  Cindy Neunert; Wendy Lim; Mark Crowther; Alan Cohen; Lawrence Solberg; Mark A Crowther
Journal:  Blood       Date:  2011-02-16       Impact factor: 22.113

4.  Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia.

Authors:  Michele P Lambert; Char M Witmer; Janet L Kwiatkowski
Journal:  Am J Hematol       Date:  2017-03-20       Impact factor: 10.047

5.  Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis.

Authors:  Joyce Tumaini Massaro; Yanhui Chen; Zhongling Ke
Journal:  Platelets       Date:  2019-02-27       Impact factor: 3.862

6.  Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.

Authors:  Douglas B Cines; Terry Gernsheimer; Jeffrey Wasser; Bertrand Godeau; Drew Provan; Roger Lyons; Ivy Altomare; Xuena Wang; Angela Lopez
Journal:  Int J Hematol       Date:  2015-07-23       Impact factor: 2.490

Review 7.  International consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Roberto Stasi; Adrian C Newland; Victor S Blanchette; Paula Bolton-Maggs; James B Bussel; Beng H Chong; Douglas B Cines; Terry B Gernsheimer; Bertrand Godeau; John Grainger; Ian Greer; Beverley J Hunt; Paul A Imbach; Gordon Lyons; Robert McMillan; Francesco Rodeghiero; Miguel A Sanz; Michael Tarantino; Shirley Watson; Joan Young; David J Kuter
Journal:  Blood       Date:  2009-10-21       Impact factor: 22.113

Review 8.  Eltrombopag for use in children with immune thrombocytopenia.

Authors:  Taylor Olmsted Kim; Jenny Despotovic; Michele P Lambert
Journal:  Blood Adv       Date:  2018-02-27

9.  Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.

Authors:  Michael D Tarantino; James B Bussel; Victor S Blanchette; Donald Beam; John Roy; Jenny Despotovic; Ashok Raj; Nancy Carpenter; Bhakti Mehta; Melissa Eisen
Journal:  Haematologica       Date:  2019-03-07       Impact factor: 9.941

10.  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Romiplostim on Health-Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents.

Authors:  Susan D Mathias; Xiaoyan Li; Melissa Eisen; Nancy Carpenter; Ross D Crosby; Victor S Blanchette
Journal:  Pediatr Blood Cancer       Date:  2016-04-01       Impact factor: 3.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.